VBI Vaccines Stock Price and Value Analysis

Should you buy VBI Vaccines stock? (NasdaqCM:VBIV). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company has fluctuating growth.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

VBIV Free Cash Flow Trend

Hmm, we can't give any reliable projection for VBI Vaccines's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for VBIV
Free Cash Flow trendline for VBI Vaccines

Inside the VBIV Numbers

VBIV Price
(VBI Vaccines stock price per share)
$1.97
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 57.8% higher than other Biotechnology stocks
[?] Free Cash Flow Jitter 26%

Is VBI Vaccines Stock on Sale?

Based on our analysis, we believe that you should not buy VBI Vaccines right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy VBIV Stock?

Does VBI Vaccines have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.